"Ooh...He's Got Double Vision:" Lithium-Induced Ocular Myasthenia Gravis in An Older Adult Male
Zobia Chunara,Erica Garcia-Pittman
DOI: https://doi.org/10.1016/j.jagp.2024.01.153
2024-04-01
Abstract:Introduction Lithium is widely used in the geriatric patient population for the maintenance of bipolar disorder as a relatively safe option that is neuroprotective. However, it is still important to obtain a thorough history of patients' medical conditions and be aware of and educate patients on side effects both generally and specific to patients' comorbidities. Even when lithium is within therapeutic range on labs, the overall incidence of side effects on the nervous system ranges from 35% to 50%. Neurologic effects include a postural tremor and cognitive effects (dysphoria, slowed reaction times, impaired memory). Uncommon neurologic adverse effects include mild parkinsonism, ataxia, and dysarthria. Lithium is rarely associated with peripheral neuropathy, pseudotumor cerebri, increased seizure risk, and findings resembling myasthenia gravis. Myasthenia gravis is an autoimmune disease in which antibodies destroy the communication between nerves and muscle, resulting in weakness of muscles of the body. Ocular myasthenia gravis affects muscles that move the eyes and eyelids. Symptoms include double vision, blurry vision, and ptosis. There exist only a couple of case reports documenting lithium exposing or exacerbating myasthenia gravis. In this abstract, we discuss the case of a geriatric patient with bipolar disorder who experienced exacerbation of ocular myasthenia while initiating low dose lithium despite a low lithium level. Methods Mr. T, a 67-year-old Caucasian male with a past psychiatric history of bipolar disorder, type2 and past medical history of ocular myasthenia gravis, hypothyroidism (status post thyroidectomy), chronic pancreatitis, and spinal stenosis presented to the outpatient geriatric psychiatry clinic in search of a new psychiatric provider in 2016. In 2011, Mr. T experienced diplopia in all visual fields when looking straight ahead and to the right. Diplopia worsened with increased physical exertion. He was initiated on pyridostigmine 80mg three times per day by a neuro-ophthalmologist with resolution of diplopia. In an attempt to consolidated Mr. T's medications (seroquel and lamotrigine with partial resolution of bipolar depression), we considered lithium a relatively safe and effective option. Mr. T initiated lithium 300mg at bedtime. Within four days, Mr. T started experiencing diplopia akin to that he had experienced five years prior, indicating exacerbation of ocular myasthenia gravis. Mr. T was no longer able to function in his daily life, and normal activities such as watching TV, walking, and driving were not possible. One week after initiation, labs showed a low lithium of 0.30 and normal CBC, CMP, TSH, FT4, FT3, lipid panel. Mr. T stopped taking lithium two weeks after initiation. Results When Mr. T stopped taking lithium, he did not notice improvement in diplopia until several weeks later. He visited his neuro-ophthalmologist who confirmed that his ocular myasthenia gravis has reemerged, but his pyridostigmine dose was continued at the same dosage. During this time, Mr. T continued to take lamotrigine and quetiapine as he had before for bipolar disorder, and his medications were evaluated again while he was monitored for any other lithium side effects. Conclusions Given that there are a handful of geriatric patients with worsening myasthenia gravis on lithium for bipolar disorder or depression, providers should evaluate patient's medical co-morbidities and warn patients of possible exacerbation of myasthenia gravis related symptoms with use of lithium or increase in lithium dose. If side effects do occur, providers should diligently review the symptoms thoroughly, consider the role of medications and co-morbidities and collaborate with other medical specialties to determine the primary etiology and guide management.
psychiatry,geriatrics & gerontology,gerontology